Lucchesi Vanessa Haguihara, Giorgetti Ana Paula Oliveira, Corrêa Mônica Grazieli, Pecorari Vanessa G A, Benatti Bruno Braga, Tenenbaum Howard C, Cirano Fabiano Ribeiro, Pimentel Suzana Peres, Casati Márcio Zafallon
Dental Research Division, Scholl of Dentistry, Universidade Paulista (UNIP), São Paulo, São Paulo, Brazil.
Dental Research Division, Biostatistcs Department, Scholl of Dentistry, Universidade Paulista (UNIP), São Paulo, São Paulo, Brazil.
Clin Oral Investig. 2025 Aug 30;29(9):428. doi: 10.1007/s00784-025-06517-9.
Smoking patients demonstrate an elevated risk of periodontitis development and respond poorly to periodontal therapy as compared to nonsmokers, and resveratrol (RSV) demonstrated a positive effect in the reduction of periodontitis progression in both animal and clinical trials. However, to the authors' knowledge, no clinical study has assessed the impact of resveratrol under smoking conditions. Thus, this trial aimed to evaluate the effect of systemic administration (SA) of RSV adjunct to full-mouth ultrasonic debridement (FMUD) of periodontitis smoking patients (PSP).
Thirty-eight individuals were randomly assigned to two groups:Placebo ( n = 19) -FMUD and placebo for 180 days; RSV ( n = 19) FMUD and RSV (500 mg/day) for 180 days. Clinical and immunoinflammatory outcomes were assessed at baseline, 3-, 6-, and 12-months post-therapy, and microbiological outcomes were evaluated at baseline, 3-, 6- months post-therapy.
RSV appeared to induce lower PD [2.96 (0.41) - 3 months; 2.85 (0.40) - 6 months; 2.80 (0.35)- 12 months], CAL [4.02 (0.90) - 3 months; 4.04 (0.81) - 6 months; 3.87 (0.78) - 12 months], and PMG [2.20 (0.56) - 3 months; 2.28 (1.14) - 6 months; 2.32 (3.27) - 12 months] readings as compared to Placebo [PD: 3.22 (0.51) - 3 months; 3.07 (0.42) - 6 months; 3.02 (0.42) - 12 months; CAL: 4.43 (0.99) - 3 months; 4.24 ((0.89) - 6 months; 4.39 (0.93) - 12 months; PMG: 2.50 (0.50) - 3 months; 2.53 (0.45) - 6 months; 2.67 (0.46) - 12 months] throughout the time (p < 0.05). The concentration of Aggregatibacter actinomycetemcomitans (Aa) was significantly higher in moderate [2.29 (1.10); 1.61 (1.02) for PL and RSV, respectively] and deep PD [2.39 (1.14); 1.73 (0.90) for PL and RSV respectively] at 3 months for the Placebo group (p < 0.05). Additionally, Aa levels were lower at 6 months in the deep sites for the RSV group (p < 0.05) [1.77 (0.94); 2.23 (1.08) for PL and RSV, respectively]. Immunoinflammatory analysis showed lower levels of IL-1β at 3-month periods in deep sites in the RSV group [92.6 ± 84.2; 35.36 (52.92) for PL and RSV, respectively] and lower concentrations of IL-6 in the RSV group at 3 and 12 months in both moderate [8.11 (9.50); 4.67 (4.20) - 3 months for PL and RSV, respectively; 8.01 ± 3.52; 5.33 (4.14) - 12 months for PL and RSV, respectively]; and deep sites [4.69 (3.06); 3.57 (3.73) - 3 months for PL and RSV, respectively]; 3.50 (2.67); 2.10 (0.89) - 12 months for PL and RSV, respectively] (p < 0.05).
In conclusion, systemic administration of RSV improves clinical results and modulates IL-1β at 3 months, IL-6 at 3- and 6- months, in deep sites of smoking patients when associated with FMUD.
Rebec identifier https//ensaiosclinicos.gov.br/rg/RBR3gt65c.
与不吸烟者相比，吸烟患者患牙周炎的风险更高，且对牙周治疗的反应较差，白藜芦醇（RSV）在动物和临床试验中均显示出对减缓牙周炎进展有积极作用。然而，据作者所知，尚无临床研究评估吸烟情况下白藜芦醇的影响。因此，本试验旨在评估全身给药（SA）的白藜芦醇辅助全口超声清创术（FMUD）对吸烟的牙周炎患者（PSP）的效果。
38名个体被随机分为两组：安慰剂组（n = 19）——接受FMUD并服用安慰剂180天；白藜芦醇组（n = 19）——接受FMUD并服用白藜芦醇（500毫克/天）180天。在基线、治疗后3个月、6个月和12个月评估临床和免疫炎症结果，在基线、治疗后3个月和6个月评估微生物学结果。
与安慰剂组相比，白藜芦醇组在整个观察期内的牙周袋深度[2.96（0.41）——3个月；2.85（0.40）——6个月；2.80（0.35）——12个月]、临床附着丧失[4.02（0.90）——3个月；4.04（0.81）——6个月；3.87（0.78）——12个月]和探诊出血[2.20（0.56）——3个月；2.28（1.14）——6个月；2.32（3.27）——12个月]读数似乎更低[安慰剂组：牙周袋深度：3.22（0.51）——3个月；3.07（0.42）——6个月；3.02（0.42）——12个月；临床附着丧失：4.43（0.99）——3个月；4.24（0.89）——6个月；4.39（0.93）——12个月；探诊出血：2.50（0.50）——3个月；2.53（0.45）——6个月；2.67（0.46）——12个月]（p < 0.05）。安慰剂组在3个月时，中度[分别为2.29（1.10）；白藜芦醇组为1.6A放线杆菌（Aa）的浓度在安慰剂组的牙周袋深度[分别为2.39（1.14）；白藜芦醇组为1.73（0.90）]和深度牙周袋中显著更高（p < 0.05）。此外，白藜芦醇组在6个月时深部位点的Aa水平较低（p < 0.05）[分别为1.77（0.94）；安慰剂组为2.23（1.08）]。免疫炎症分析显示，白藜芦醇组在3个月时深部位点的IL - 1β水平较低[分别为92.6 ± 84.2；安慰剂组为35.36（52.92）]，白藜芦醇组在3个月和12个月时中度位点[分别为8.11（9.50）；白藜芦醇组为4.67（4.20）——3个月；8.01 ± 3.52；白藜芦醇组为5.33（4.14）——12个月]和深部位点[分别为4.69（3.06）；白藜芦醇组为3.57（3.73）——3个月；3.50（2.67）；白藜芦醇组为2.10（0.89）——12个月]的IL - 6浓度较低（p < 0.05）。
总之，全身给药的白藜芦醇与FMUD联合使用时，可改善吸烟患者深部位点的临床结果，并在3个月时调节IL - 1β，在3个月和6个月时调节IL - 6。
Rebec标识符https//ensaiosclinicos.gov.br/rg/RBR3gt65c。
Zotero 插件